Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Implantica

40.00 SEK

-0.62 %

Less than 1K followers

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

-0.62 %
-13.42 %
-20.16 %
-16.67 %
-35.28 %
+25.39 %
+49.25 %
-68.90 %
-58.57 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Read more
Market cap
47.33B SEK
Turnover
588.38K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22.5.
2026

Interim report Q1'26

10.6.
2026

General meeting '26

21.8.
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Implantica’s RefluxStop® sparked great enthusiasm at the American Foregut Society meeting in the United States ahead of the expected FDA approval. Medtech company Implantica presented its RefluxStop® implant, developed for the treatment of acid reflux, at the AFS annual meeting in...
9/17/2025, 6:49 AM
by Pevitaha
4
Vahva on luotto firmalla, että FDA hyväksyntä tulee, kun on kehitetty uusi tuotantolaite jolla saadaan nopeammin valmistettua RefluxStopia. Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval logo ...
8/13/2025, 6:59 AM
by Pevitaha
3
Tämä ketju on ollut hyvin hiljainen. Implantica on kuitenkin ollut hyvin kiinnostava taas viime kesästä alkaen, kun potilaiden seurannan tuloksia julkaistiin. Nyt FDA on antanut positiivista palautetta, koskien moduuli 2:ta hakuprosessissa. Tämä on kattavin ja tärkein moduuleista...
2/13/2025, 7:16 AM
by KimiN
3
Implanticas Q3’25 webcast: Inderes Implantica, Webcast, Q3'25 - Inderes Time: 2025-10-31 15:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference
11/4/2025, 12:40 PM
by Isa Hudd
2
Toinen julkaisu RefluxStopin viiden vuoden seurannan tuloksista. Eihän tässä voi kuin odotella FDA hyväksynnän tuloksia, jotka toivottavasti tulee tässä lähiaikoina (autumn). implantica.com Implantica announces second publication of groundbreaking 5-year results from... Implantica...
8/7/2025, 7:00 AM
by Pevitaha
2
Tykkään tästä vertailusta toiseen hoitotapaan ja sen mahdollisiin haittavaikutuksien vs RefluxStop. Aika merkittävästi vähemmän haittavaikutuksia esiintyy RefluxStop vs Nissen Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating...
7/1/2025, 11:47 AM
by Pevitaha
2
Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval logo Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval Implantica AG (publ.), a MedTech company at the forefront...
6/24/2025, 6:10 AM
by Pevitaha
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.